Global Microbiome Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Microbiome Therapeutics Market Growth (Status and Outlook) 2023-2029

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

LPI (LP Information)' newest research report, the “Microbiome Therapeutics Industry Forecast” looks at past sales and reviews total world Microbiome Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Microbiome Therapeutics sales for 2023 through 2029. With Microbiome Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Microbiome Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Microbiome Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Microbiome Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Microbiome Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Microbiome Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Microbiome Therapeutics.

The global Microbiome Therapeutics market size is projected to grow from US$ 89 million in 2022 to US$ 916.3 million in 2029; it is expected to grow at a CAGR of 39.5% from 2023 to 2029.

The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.

For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.

North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.

Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.

This report presents a comprehensive overview, market shares, and growth opportunities of Microbiome Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Upper GIT

Lower GIT

Segmentation by application

C. difficile Infection (CDI)

Inflammatory Bowel Disease (IBD)

Orphan Drug

Immuno-oncology

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

C3 Jian

Rebiotix

MicroBiome Therapeutics LLC

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Symbiotix Biotherapies

Osel

Metabogen

Please note: The report will take approximately 2 business days to prepare and deliver.